KR20000072005A - The method of preparing for urinary calculus lithiasis for reatment(crystal type) - Google Patents

Abstract

PURPOSE: A method of preparing treatment for urolithiasis is provided, which forms a specific type of powder or particulate of the treatment, to give a convenience in administration and portability, an excellent stability in its storage, a preference for selecting the treatment caused by using various other auxiliary agents, and a supplementary effect such as a remarkable cost reduction for its circulation or preparation. CONSTITUTION: An agent for treating or removing calculus in a urinary tract is characterized of comprising potassium citrate and citric acid as major components, and one or more types of auxiliary agents as minor components selecting from the group of a seasoning agent, a sliding and lustering agent, a flavoring agent, a coloring agent and the like. Alternatively, the sliding and lustering agent is characterized by being a silicate dioxide.

Description

The method of preparing for urinary calculus lithiasis for reatment (crystal type) in the treatment of urolithiasis based on potassium citrate

The present invention relates to a method for producing powders and crystals which can effectively treat urine stones on the subject of potassium citrate and citric acid. More specifically, in the present invention, potassium citrate and citric acid are shaken and mixed to prepare granules. In order to prevent moisture absorption of potassium citrate, which is a main ingredient, a lubricant such as silicon dioxide is added and formulated into granules of a certain size so that the patient's dose is reduced. It relates to a manufacturing method that can maximize the shelf life as well as easy to ensure the stability of the formulation.

Urinary tract stones are an advanced national condition that is steadily increasing due to improved living standards and changes in diet, and is a common disease in urology, accounting for more than 25% of patients visiting urology. The main constituents of these stones are calcium, oxalic acid, phosphoric acid and uric acid. Rarely, magnesium ammonium phosphate salt, cystine and the like are used. Urinary stones can be easily formed when these components are excreted in urine excessively, and the factors that promote their crystallization and crystallization include urine acidity, urinary tract infection, and urinary tract stagnation. The most common symptom of urinary tract stones is the development of colic and hematuria. Colic is caused by excessive peristalsis of the urinary tract muscles due to sudden urinary tract obstruction, renal capsules, and pyelonephritis. These pains appear on the back, side, abdomen, etc., and the extent is so severe that the patient's pain can not be expressed in words. Pain may be persistent or intermittent, accompanied by nausea, vomiting, hematuria, and other urination disorders or urination pain.

In general, stones are classified into kidney stones, ureter stones, and bladder stones according to the generation site.The most commonly used methods of treatment include extracorporeal shock wave lithotripsy, a 1-2 cm skin incision. Transcutaneous lithotripsy, which removes stones by endoscopic injection, and methods of removing stones by laparotomy are used. However, despite their effective treatments, the recurrence rate of the stones is 70-80%, which means that an alternative to post-treatment drug therapy is indispensable. However, potassium citrate and citric acid, which are effective in the treatment of stones, are too difficult to be consumed by patients because of their one-time effective intake, and the liquid formulations currently in use are difficult to store and there is a risk of crystal precipitation in long-term storage. Zero research was urgent.

In order to solve the above problems, the present inventors have developed and completed a solid preparation of urinary stones for treating urinary stones according to such a necessity. It was formulated to be convenient for the patient to add. In addition, in order to prevent the hygroscopic action caused by the physicochemical properties of potassium citrate, the main component, a manufacturing method is established in which stability can be secured by adding a lubricant. In addition, the present invention has been completed in order to contribute to the convenience of treatment and administration of patients with urinary tract stones at home and abroad by packaging the powder and fine particles prepared by the above-described method in a special silver foil container once.

Accordingly, an object of the present invention is a novel urea obtained by adding potassium citrate and citric acid as a main component, adding one or more auxiliary ingredients selected from sweeteners, lubricants, colorants, flavoring agents, etc. It is to provide a method of preparing a stone medicine and a special package for convenience of taking and carrying.

In order to achieve the above object, the applicant of the present invention is filed in Korean Patent Application No. 10-1999-39110 filed with a prior application of the present invention: to improve the manufacturing method of the urinary stone treatment agent mainly based on potassium citrate, It contains potassium citrate and citric acid more than 3000 ~ 4000mg, 900 ~ 1100mg per 5g respectively as a main ingredient and any compound selected from mannitol, glucose, fructose, fructose, sorbitol, aspartame, stevioside as a sweetening agent, silicon dioxide, as a lubricant The main and auxiliary ingredients are determined by the type and particle size of the excipient when prepared using any compound selected from magnesium stearate, stearic acid and talc, and any one selected from strawberry, cherry, peppermint, and vanilla flavors as a flavoring agent. It includes a manufacturing process that can ensure the stability of the formulation by minimizing the adsorption of.

Sweeteners that can be used in the present invention may use any compound selected from mannitol, glucose, white sugar, fructose, isomerized sugar, maltose, oligosaccharide, sorbitol, aspartame, stevioside, and other conventional sweeteners,

The glidants used in the present invention are silicon dioxide, magnesium stearate, stearic acid, talc and other commonly used glidants.

As the flavoring agent used in the present invention, orange flavor, strawberry flavor, cherry flavor, peppermint flavor, vanilla flavor and the like and their essences can be used.

The present invention is a method for preparing powders and conventional solid preparations that are effective in treating stones, in particular, when preparing 5g of powder, 3,000 to 4000 mg of potassium citrate and 900 to 1100 mg of citric acid are added. 5 to 20 mg of aspartame is prepared by mixing 100 to 600 mg of silicon dioxide with a lubricant and 2 mg or less of strawberry flavor as a flavoring agent. That is, in consideration of the adsorptivity of the components at the time of their addition was prepared as follows as a part for preventing the moisture absorption.

Schematic diagram of the manufacturing method for the production of 5g powder

Raw material selection

↓ · shaker: 500 μm or less to 75 μm or more

Raw material weighing

↓ · Weighing scales: Potassium citrate, citric acid, sweeteners, lubricants, flavoring agents

Ovulation mixing

↓ ・ Potassium citrate, citric acid mixture

mix

↓ ・ Addition of lubricant (silicon dioxide)

↓ · sweetener, flavoring agent added

Formulations

↓ ・ 500μm or less to 75μm or more only

Small packing

↓ · silver foil packing

product

Through the following examples will be described in detail the present invention.

Example 1

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 370mg

Aspartame 10mg

Silicon dioxide 300mg

Red No. 40

Strawberry flavor

----------------------------------------

5000mg

The above ingredients are prepared according to the conventional powder preparation method and filled in high-resolution silver foil.

Example 2

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 370mg

Aspartame 10mg

Magnesium Stearate 300mg

Red No. 40

Strawberry flavor

----------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 3

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 270mg

Aspartame 10mg

Silicon Dioxide 400mg

Red No. 40

Strawberry flavor

----------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 4

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 470mg

Aspartame 10mg

200mg of silicon dioxide

Red No. 40

Strawberry flavor

-----------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 5

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 370mg

Aspartame 10mg

Magnesium Stearate 300mg

Red No. 40

Strawberry flavor

----------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 6

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 270mg

Aspartame 10mg

Magnesium Stearate 400mg

Red No. 40

Strawberry flavor

------------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 7

Potassium Citrate 3300mg

Citric Acid 1002mg

Mannitol 470mg

Aspartame 10mg

Magnesium Stearate 200mg

Red No. 40

Strawberry flavor

------------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 8

Potassium Citrate 3300mg

Citric Acid 1002mg

Sorbitol 380mg

Silicon dioxide 300mg

Red No. 40

Strawberry flavor

-------------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 9

Potassium Citrate 3300mg

Citric Acid 1002mg

Sorbitol 380mg

Magnesium Stearate 300mg

Red No. 40

Strawberry flavor

-------------------------------------------

5000mg

The above ingredients are prepared according to the method of Example 1.

Example 10 (soft capsule)

Potassium Citrate 440mg

Citric Acid 133.6mg

Vitamin E 8-20mg

Soybean Lecithin 5-30mg

Beeswax 25mg

Soybean oil 388.4-351.4 mg

---------------------------------------------

1,000mg

The soft capsule is prepared according to the conventional method for producing a soft capsule.

Example 11 (Tablet)

Potassium Citrate 440mg

Citric Acid 133.6mg

Starch 240mg

Beeswax 20mg

6.4mg of silicon dioxide

Cellulose 10mg

Lactose 150mg

-------------------------------------------

1,000mg

Tablets are prepared according to the above-described method for producing tablets.

The following experiments are the results of experiments on the stability and safety of powders using one or more auxiliary ingredients selected from other sweeteners, lubricants, fragrances, etc., based on citric acid and potassium citrate.

Experimental Example 1

1) Experiment Method

Examples prepared with each powder were stored for 6 months at room temperature and 40 ° C. ± 1 ° C., 75% RH ± 5% conditions, and then the size and content of the particle size were determined after 2 months, 4 months, and 6 months. The particle size test is conducted according to the particle size test method of powder of the Korean Pharmacopoeia Formulation, and the content test is precisely weighed about 2 g of potassium citrate and dissolved in water to make exactly 200 mL of potassium as the main component. 50 μL of this solution is diluted to 10 mL with lithium diluent solution and tested according to the Assay for Potassium in the section of Potassium Citrate and Citric acid Oral Solution. About citrate in the main component, about 5 g of Example is weighed, dissolved in water to make exactly 250 mL, and filtered if necessary. Take 5 mL of this solution and test it according to the assay for citrate in the section "Potassium Citrate and Citric acid Oral Solution". About citric acid among the main components, weigh about 5 g in the run, dissolve in water to make exactly 250 mL, and filter if necessary. Take 5 mL of this solution and test it according to the assay for citric acid in the section "Potassium Citrate and Citric acid Oral Solution".

2) Experiment result

As shown in Table 1, Table 2, Table 3, and Table 4, there was almost no change in particle size and content in the stability test of each Example. Therefore, the stability of the preparation according to the present invention was confirmed.

Table 1. Result of particle size test of each Example stored at room temperature

Test Items standard Example Result Manufacture immediately 2 months later 4 months later 6 months later Mouth dildo 10% or less of the total amount is passed through the whole sieve of 500㎛ and passed through 74㎛ sieve One fitness fitness fitness fitness 2 fitness fitness fitness fitness 3 fitness fitness fitness fitness 4 fitness fitness fitness fitness 5 fitness fitness fitness fitness 6 fitness fitness fitness fitness 7 fitness fitness fitness fitness 8 fitness fitness fitness fitness 9 fitness fitness fitness fitness

Table 2. Result of particle size test of each Example stored at 40 ± 1 ℃, 70% RH ± 5%

Test Items standard Example Result Manufacture immediately 2 months later 4 months later 6 months later Mouth dildo 10% or less of the total amount is passed through the whole sieve of 500㎛ and passed through 74㎛ sieve One fitness fitness fitness fitness 2 fitness fitness fitness fitness 3 fitness fitness fitness fitness 4 fitness fitness fitness fitness 5 fitness fitness fitness fitness 6 fitness fitness fitness fitness 7 fitness fitness fitness fitness 8 fitness fitness fitness fitness 9 fitness fitness fitness fitness

Table 3. Result of content test of each Example stored at room temperature

Test Items standard Example Result Manufacturing 2 months later 4 months later 6 months later content Cerium 90-110% One 103.5% 98.2% 98.6% 96.7% 2 102.7% 99.7% 98.4% 97.3% 3 101.0% 97.8% 97.8% 97.4% 4 102.8% 99.5% 98.1% 97.5% 5 100.6% 98.9% 95.7% 95.8% 6 101.4% 99.3% 97.5% 97.0% 7 101.7% 98.3% 97.4% 96.6% 8 103.3% 99.1% 97.1% 96.7% 9 102.4% 99.9% 98.4% 96.3% citrate 90-110% One 100.17% 99.95% 99.28% 98.37% 2 101.22% 99.73% 98.76% 97.55% 3 102.01% 100.31% 97.34% 97.86% 4 100.24% 99.90% 99.23% 98.30% 5 103.12% 99.87% 98.47% 97.98% 6 100.16% 99.94% 99.15% 98.47% 7 101.24% 99.21% 98.65% 96.89% 8 100.19% 99.93% 99.22% 98.38% 9 105.35% 99.34% 98.46% 97.65% Citric acid 90-110% One 100.03% 99.78% 99.08% 98.26% 2 102.45% 100.02% 98.43% 97.53% 3 102.31% 100.34% 98.54% 97.82% 4 100.04% 99.66% 99.09% 98.22% 5 101.25% 99.54% 98.12% 97.65% 6 100.01% 99.79% 99.09% 98.18% 7 103.17% 98.85% 97.56% 97.12% 8 100.03% 99.75% 99.09% 98.22% 9 102.24% 99.14% 98.265 97.57%

Table 4. Result of content test of each Example stored at room temperature

Test Items standard Example Result Manufacturing 2 months later 4 months later 6 months later content Cerium 90-110% One 103.1% 98.0% 98.5% 96.5% 2 102.5% 99.6% 98.2% 97.0% 3 100.8% 97.5% 97.7% 97.1% 4 102.5% 99.3% 98.0% 97.2% 5 100.1% 98.8% 95.5% 95.5% 6 101.3% 99.2% 97.3% 96.8% 7 101.4% 98.1% 97.2% 96.4% 8 103.1% 98.9% 97.0% 96.6% 9 102.2% 99.7% 98.1% 96.1% citrate 90-110% One 100.16% 99.94% 99.26% 98.34% 2 101.20% 99.71% 98.74% 97.52% 3 102.00% 100.29% 97.32% 97.85% 4 100.21% 99.87% 99.20% 98.28% 5 103.13% 99.85% 98.44% 97.97% 6 100.14% 99.92% 99.13% 98.45% 7 101.22% 99.21% 98.61% 96.86% 8 100.17% 99.90% 99.21% 98.37% 9 105.32% 99.32% 98.45% 97.62% Citric acid 90-110% One 100.01% 99.75% 99.05% 98.24% 2 102.44% 100.01% 98.41% 97.51% 3 102.30% 100.31% 98.52% 97.80% 4 100.01% 99.65% 99.07% 98.21% 5 101.22% 99.52% 98.10% 97.62% 6 100.00% 99.77% 99.05% 98.16% 7 103.14% 98.84% 97.53% 97.11% 8 100.00% 99.73% 99.04% 98.20% 9 102.20% 99.12% 98.261 97.55%

The following experiments are the results of acute toxicity test (single dose toxicity test) using the powders of Examples 1-9 based on potassium citrate and citric acid, which are the subjects of the present invention.

Experimental Example 2

1) Animal Experiment

Experimental animals were used after acclimatization to the laboratory environment for two weeks while feeding a solid feed and water sufficiently using a CDFI mouse of 15-20g body weight.

2) Experiment Method

The experimental animals were divided into 10 groups into 1 group and 10 groups. The acute toxicity test was performed to obtain LD ₅₀ by the Behrens-Karber method.

In each group, the powders prepared in each example were dissolved in purified water of 200 ml or more, and the doses were increased in an equal amount from 1 mL / Kg to 10 mL / Kg.

3) Experiment result

As shown in Table 2, there was no lethal for each dose oral (po) route of administration, the potassium citrate and citric acid used in the present invention as the main component, at least one auxiliary agent selected from sweeteners, lubricants, flavors, coloring agents, etc. Powders prepared by adding the ingredients were found to have little toxicity.

Table 5. Toxicity test results of the liquid preparations prepared in Examples 1-9

Dose (mL / Kg) The number of animals Route of administration Deadly animals 1 2 3 4 5 6 7 8 9 10 10101010101010101010 p.op.op.op.op.op.op.op.op.op.o 0/100/100/100/100/100/100/100/100/100/10

In the present invention as described above, in the preparation of potassium citrate and citric acid, which have an excellent effect on urinary stones, based on the treatment prescription, a convenient formulation, easy to carry, and excellent stability of powder formulations have been studied. Use was made to allow patients to easily take the drug of the present invention without objection. In addition, the present invention, by using the silicon dioxide which can effectively prevent the moisture absorption between the main components due to the strong hygroscopicity of the main components, as well as showing a certain gliding effect, as well as the secondary effect of reducing the distribution and manufacturing costs by extending the shelf life. Is there.

Claims (6)

The urolithiasis therapeutic composition, which comprises potassium citrate and citric acid as a main component, and is added to at least one auxiliary component selected from sweeteners, lubricants, fragrances, coloring agents, and the like to form a powder. Potassium citrate according to claim 1, characterized in that it is composed of at least one auxiliary ingredient selected from sweeteners, fragrances and coloring agents as potassium citrate 3000 to 4000 mg, citric acid 990 to 1100 mg, silicon dioxide 100 to 600 mg, and other auxiliary ingredients in 5g and Urinary stone therapy composition containing citric acid as a main component. The urolithiasis therapeutic composition according to claim 1, wherein the composition comprises potassium citrate and citric acid as main components, which is composed of magnesium stearate instead of 100 to 600 mg of silicon dioxide. The pharmaceutical formulation of claim 1, wherein potassium citrate and citric acid are used as a main ingredient, and at least one excipient selected from conventional sweeteners, fragrances, coloring agents, and the like is formulated in a conventional formulation form in a conventional manner. In the preparation method of the urinary tract stone treatment composition based on potassium citrate, when preparing 5 g of powder, 3,000 to 4000 mg of potassium citrate and 900-1100 mg of citric acid are taken as main ingredients, and 300 to 600 mg of mannitol and 5 to 20 mg of aspartame as sweeteners. A method for preparing a urinary stone treatment composition based on potassium citrate, characterized by mixing 100 to 600 mg of silicon dioxide as a lubricant and using less than 2 mg of strawberry flavor as a flavoring agent. 5. The stabilization of the urinary stone therapy composition based on potassium citrate according to claim 4, wherein the composition is stabilized by adding at least 2.0 to 12.0% of silicon dioxide by adding sweeteners, lubricants, fragrances, and coloring agents to citric acid and potassium citrate. Way.